No Long COVID Drugs Yet, But Other Treatments Available

Allison Saulino, 46, lengthy COVID advocate, Hilliard, OH.

David Putrino, PhD, director of rehabilitation innovation, Mount Sinai Health System, New York City.

Andrew Schamess, MD, professor of inner drugs, Ohio State Wexner Medical Center, who runs the Post-COVID Recovery Program.

Daniel Sterman, MD, director, Division of Pulmonary, Critical Care and Sleep Medicine, NYU Langone Health, New York City.

Jennifer Frontera, MD, neurologist, NYU Langone Health.

Journal of Neurological Science: “Mid and Long-Term Neurological and Neuropsychiatric Manifestations of Post-COVID-19 Syndrome: A Meta-Analysis.”

American Academy of Otolaryngology: “Smell Retraining Therapy.”

PLOS Pathogens: “SARS-CoV-2-Specific T-Cells Associate with Inflammation and Reduced Lung Function in Pulmonary Post-Acute Sequalae of SARS-CoV-2.”

Science Translational Medicine: ”SARS-CoV-2 Infection Produces Chronic Pulmonary Epithelial and Immune Cell Dysfunction with Fibrosis in Mice.”

Rheumatic & Musculoskeletal Diseases: “Fibromyalgia: a New Facet of the Post-COVID-19 Syndrome Spectrum? Results From A Web-Based Survey.”

Journal of Thrombosis and Haemostasis: “Persistent Endotheliopathy in the Pathogenesis of Long COVID Syndrome.”

International Forum of Allergy and Rhinology: “Budesonide Irrigation with Olfactory Training Improves Outcomes Compared with Olfactory Training Alone in Patients with Olfactory Loss.”

Oregon Health & Science University: “Clinical Guidelines: Long COVID-19.”